荃信生物(02509.HK)QX002N治疗脊柱炎III期临床试验达主要终点

阿斯达克财经
Feb 24

荃信生物-B(02509.HK) 公布,公司自主研发的QX002N注射液用于治疗强直性脊柱炎的III期临床试验达到主要终点。数据显示,QX002N在中重度活动性强直性脊柱炎患者中展出优异的疗效以及良好的安全性和耐受性。(de/d)(港股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10